MGI Pharma coverage started

U.S. Bancorp Piper Jaffray analyst Peter Ginsberg began coverage of MOGN with a "strong-buy" and a $50 price target. He said that the company's Irofulven chemotherapeutic for difficult-to-treat cancer...